Data-Derived Modeling Characterizes Plasticity of MAPK Signaling in Melanoma

The majority of melanomas have been shown to harbor somatic mutations in the RAS-RAF-MEK-MAPK and PI3K-AKT pathways, which play a major role in regulation of proliferation and survival. The prevalence of these mutations makes these kinase signal transduction pathways an attractive target for cancer therapy. However, tumors have generally shown adaptive resistance to treatment. This adaptation is achieved in melanoma through its ability to undergo neovascularization, migration and rearrangement of signaling pathways. To understand the dynamic, nonlinear behavior of signaling pathways in cancer, several computational modeling approaches have been suggested. Most of those models require that the pathway topology remains constant over the entire observation period. However, changes in topology might underlie adaptive behavior to drug treatment. To study signaling rearrangements, here we present a new approach based on Fuzzy Logic (FL) that predicts changes in network architecture over time. This adaptive modeling approach was used to investigate pathway dynamics in a newly acquired experimental dataset describing total and phosphorylated protein signaling over four days in A375 melanoma cell line exposed to different kinase inhibitors. First, a generalized strategy was established to implement a parameter-reduced FL model encoding non-linear activity of a signaling network in response to perturbation. Next, a literature-based topology was generated and parameters of the FL model were derived from the full experimental dataset. Subsequently, the temporal evolution of model performance was evaluated by leaving time-defined data points out of training. Emerging discrepancies between model predictions and experimental data at specific time points allowed the characterization of potential network rearrangement. We demonstrate that this adaptive FL modeling approach helps to enhance our mechanistic understanding of the molecular plasticity of melanoma.

[1]  D. Lauffenburger,et al.  A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines*S , 2005, Molecular & Cellular Proteomics.

[2]  D. Lauffenburger,et al.  Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction , 2009, Molecular systems biology.

[3]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[4]  K. Sakaguchi,et al.  Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiation , 1999, The EMBO journal.

[5]  Elif Derya Übeyli Adaptive neuro-fuzzy inference system for classification of ECG signals using Lyapunov exponents , 2009, Comput. Methods Programs Biomed..

[6]  Michelle L. Wynn,et al.  Logic-based models in systems biology: a predictive and parameter-free network analysis method. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[7]  M. Hendrix,et al.  Molecular plasticity of human melanoma cells , 2003, Oncogene.

[8]  Ebrahim H. Mamdani,et al.  An Experiment in Linguistic Synthesis with a Fuzzy Logic Controller , 1999, Int. J. Hum. Comput. Stud..

[9]  U. Rapp,et al.  BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling* , 2011, The Journal of Biological Chemistry.

[10]  William J. Bosl,et al.  Systems biology by the rules: hybrid intelligent systems for pathway modeling and discovery , 2007, BMC Systems Biology.

[11]  Michio Sugeno,et al.  Fuzzy identification of systems and its applications to modeling and control , 1985, IEEE Transactions on Systems, Man, and Cybernetics.

[12]  L. Nelin,et al.  MAPK phosphatases — regulating the immune response , 2007, Nature Reviews Immunology.

[13]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[14]  Elif Derya Übeyli,et al.  Adaptive neuro-fuzzy inference system for classification of ECG signals using Lyapunov exponents , 2009, Comput. Methods Programs Biomed..

[15]  Y. Samuels,et al.  Analysis of the genome to personalize therapy for melanoma , 2010, Oncogene.

[16]  D. Maysinger,et al.  Cross-talk between phosphatidylinositol 3-kinase/AKT and c-jun NH2-terminal kinase mediates survival of isolated human islets. , 2004, Endocrinology.

[17]  Nils Blüthgen,et al.  Robustness of signal transduction pathways , 2012, Cellular and Molecular Life Sciences.

[18]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[19]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[20]  J. Dumont,et al.  Crosstalk and specificity in signalling. Are we crosstalking ourselves into general confusion? , 2001, Cellular signalling.

[21]  Zuyi Huang,et al.  Fuzzy modeling of signal transduction networks , 2009 .

[22]  Stephen L. Chiu,et al.  Fuzzy Model Identification Based on Cluster Estimation , 1994, J. Intell. Fuzzy Syst..

[23]  Hernán E. Grecco,et al.  Signaling from the Living Plasma Membrane , 2011, Cell.

[24]  David Hinkley,et al.  Bootstrap Methods: Another Look at the Jackknife , 2008 .

[25]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[26]  N. Mulherkar,et al.  MADD, a Splice Variant of IG20, Is Indispensable for MAPK Activation and Protection against Apoptosis upon Tumor Necrosis Factor-α Treatment* , 2009, Journal of Biological Chemistry.

[27]  Jyh-Shing Roger Jang,et al.  ANFIS: adaptive-network-based fuzzy inference system , 1993, IEEE Trans. Syst. Man Cybern..

[28]  Christina Kiel,et al.  Challenges ahead in signal transduction: MAPK as an example. , 2012, Current opinion in biotechnology.

[29]  Hong Wu,et al.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. , 2007, Cancer cell.

[30]  Trevor Hastie,et al.  An Introduction to Statistical Learning , 2013, Springer Texts in Statistics.

[31]  Peter K. Sorger,et al.  Logic-Based Models for the Analysis of Cell Signaling Networks† , 2010, Biochemistry.

[32]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[33]  M. Pincus,et al.  MEKK1/JNK signaling stabilizes and activates p53. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  F. Aoudjit,et al.  Melanoma Spheroids Grown Under Neural Crest Cell Conditions Are Highly Plastic Migratory/Invasive Tumor Cells Endowed with Immunomodulator Function , 2011, PloS one.

[35]  Julio Saez-Rodriguez,et al.  Modeling signaling networks using high-throughput phospho-proteomics. , 2012, Advances in experimental medicine and biology.

[36]  B. Kholodenko,et al.  Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. , 2000, European journal of biochemistry.

[37]  S. Chiu,et al.  A cluster estimation method with extension to fuzzy model identification , 1994, Proceedings of 1994 IEEE 3rd International Fuzzy Systems Conference.

[38]  M. Atkins,et al.  The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. , 2006, Cancer research.

[39]  Julio Saez-Rodriguez,et al.  Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling , 2007, PLoS Comput. Biol..

[40]  Roland Eils,et al.  Multi-Parametric Analysis and Modeling of Relationships between Mitochondrial Morphology and Apoptosis , 2012, PloS one.

[41]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[42]  E. Nishida,et al.  Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase , 1997, The EMBO journal.

[43]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[44]  W. Lim,et al.  Defining Network Topologies that Can Achieve Biochemical Adaptation , 2009, Cell.

[45]  Boris N. Kholodenko,et al.  Signalling ballet in space and time , 2010, Nature Reviews Molecular Cell Biology.

[46]  L. Zadeh Probability measures of Fuzzy events , 1968 .

[47]  Peter K. Sorger,et al.  Measuring and Modeling Apoptosis in Single Cells , 2011, Cell.

[48]  Julio Saez-Rodriguez,et al.  Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli , 2011, PLoS Comput. Biol..

[49]  Vasile Palade,et al.  Building interpretable fuzzy models for high dimensional data analysis in cancer diagnosis , 2011, BMC Genomics.

[50]  Penny A. Johnson,et al.  Cancer cell adaptation to chemotherapy , 2005, BMC Cancer.

[51]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.